

Analysis of timelines to availability of IPHA medicines 2022

Table 1: Summary of Timelines 2022

Average Time to availability of IPHA Medicines (2022)			
	Number of Drugs	Days to reimbursement from start of RR (in days)	Days to reimbursement from end of RR/HTA (in days)
Average time to availability of IPHA medicines in 2022	42	507	322
Average time to availability for RR only IPHA medicines in 2022	28	348	314
Average time to availability for HTA IPHA medicines in 2022	14	825	338
Average time to availability for IPHA orphan medicines in 2022	9	775	546
Average time to availability for IPHA oncology medicines in 2022	17	681	447

Table 2: Overall time to availability

	Number of Drugs	Timeline (in days)
Average time to availability of IPHA medicines in 2022	42	507

RR/ HTA	Drug Name	Brand Name	Quick indication
RR	Abrocitinib	Cibinqo	moderate-to-severe atopic dermatitis
HTA	Atezolizumab	Tecentriq	Breast Cancer
HTA	Atezolizumab	Tecentriq	extensive-stage small cell lung cancer (ES-SCLC)
HTA	Avelumab	Bavencio	locally advanced or metastatic urothelial carcinoma
	Axicabtagene		relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma
HTA	Ciloleucel	Yescarta	(PMBCL)
RR	Blinatumomab	Blinicyto	high-risk first-relapsed Ph- CD19+ B-precursor acute lymphoblastic leukaemia
	Brentuximab		
RR	vedotin	Adcetris	CD30+ cutaneous T-cell lymphoma (CTCL)
	Brentuximab		
RR	vedotin	Adcetris	previously untreated systemic anaplastic large cell lymphoma (sALCL)
	Brentuximab		
HTA	vedotin	Adcetris	CD30+ Hodgkin's lymphoma
	Cabotegravir plus	Vocabria plus	
RR	rilpivirine	Rekambys	HIV-1 infection
			combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with
HTA	Daratumumab	Darzalex	newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
HTA	Darolutamide	Nubeqa	non-metastatic castration resistant prostate cancer (nmCRPC)
	Diroximel		
RR	fumarate	Vumerity	relapsing-remitting multiple sclerosis.
RR	Dupilumab	Dupixent	severe atopic dermatitis in children 6 to 11 years old

HTA	Empagliflozin	Jardiance	symptomatic chronic heart failure
RR	Empagliflozin	Jardiance	symptomatic chronic heart failure
RR	Entrectinib	Rozlytrek	ROS1-positive advanced non-small cell lung cancer (NSCLC)
HTA	Esketamine	Spravato	Major Depressive Disorder
	Fluocinolone acetone intravitreal		
RR	implant	Iluvien	non-infectious uveitis
RR	Galcanezumab	Emgality	Migraine
	Levodopa/carbido pa/entacapone		
RR	intestinal gel	Lecigon	advanced Parkinson's disease
RR	Lorlatinib	Lorviqua	1L ALK positive NSCLC
	Nivolumab plus Ipilimumab plus platinum-doublet	Opdivo® plus	
RR	chemotherapy	Yervoy	metastatic non-small cell lung cancer (NSCLC)
RR	Ofatumumab	Kesimpta	relapsing forms of multiple sclerosis (RMS)
RR	Pembrolizumab	Keytruda	classical Hodgkin Lymphoma
	Pertuzumab and		
RR	trastuzumab	Phesgo	Early and metastatic breast cancer
RR	Pomalidomide	Imnovid	multiple myeloma
RR	Ponesimod	Ponvory	relapsing forms of multiple sclerosis (RMS)
HTA	Risankizumab	Skyrizi	moderate to severe plaque psoriasis
RR	Risankizumab	Skyrizi	active psoriatic arthritis
RR	Roxadustat	Evrenzo	treatment of adult patients with symptomatic anaemia
HTA	Siponimod	Mayzent	multiple sclerosis (SPMS)
RR	Solriamfetol	Sunosi	wakefulness and reduce excessive daytime sleepiness
RR	Somatogon	Ngenla	growth disturbance
HTA	Tafamidis	Vyndaqel	wild-type or hereditary transthyretin amyloidosis
HTA	Tildrakizumab	Illumetri	moderate to severe plaque psoriasis
RR	Tofacitinib	Xeljanz	active polyarticular juvenile idiopathic arthritis

RR	Tralokinumab	Adtralza	moderate to severe atopic dermatitis
RR	Upadacitinib	Rinvoq	moderate to severe atopic dermatitis
RR	Upadacitinib	Rinvoq	active ankylosing spondylitis (AS)
RR	Upadacitinib	Rinvoq	active psoriatic arthritis
		Venclyxto	
	Venetoclax plus	plus	
HTA	obinutuzumab	Gazyvaro	for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.

Table 3: Time to availability Rapid Review

	Number of Drugs	Timeline (in days)
Average time to availability for RR only IPHA medicines in 2022	28	348

Sr. No.	Drug Name	Brand Name	Quick indication
1	Abrocitinib	Cibinqo	moderate-to-severe atopic dermatitis
2	Blinatumomab	Blinicyto	high-risk first-relapsed Ph- CD19+ B-precursor acute lymphoblastic leukaemia
3	Brentuximab vedotin	Adcetris	CD30+ cutaneous T-cell lymphoma (CTCL)
4	Brentuximab vedotin	Adcetris	previously untreated systemic anaplastic large cell lymphoma (sALCL)
5	Cabotegravir plus rilpivirine	Vocabria plus	HIV-1 infection
6	Diroximel fumarate	Rekambyl	relapsing-remitting multiple sclerosis.
7	Dupilumab	Jardiance	severe atopic dermatitis in children 6 to 11 years old
8	Empagliflozin	Dupixent	symptomatic chronic heart failure
9	Entrectinib	Rozlytrek	ROS1-positive advanced non-small cell lung cancer (NSCLC)
10	Fluocinolone acetonide intravitreal implant	Iluvien	non-infectious uveitis

11	Galcanezumab	Emgality	Migraine
12	Levodopa/carbidopa/entacapone intestinal gel	Lecigon	advanced Parkinson's disease
13	Lorlatinib	Lorviqua	1L ALK positive NSCLC
14	Nivolumab plus Ipilimumab plus platinum-doublet chemotherapy	Opdivo® plus Yervoy	metastatic non-small cell lung cancer (NSCLC)
15	Ofatumumab	Kesimpta	relapsing forms of multiple sclerosis (RMS)
16	Pembrolizumab	Keytruda	classical Hodgkin Lymphoma
17	Pertuzumab and trastuzumab	Phesgo	Early and metastatic breast cancer
18	Pomalidomide	Imnovid	multiple myeloma
19	Ponesimod	Ponvory	relapsing forms of multiple sclerosis (RMS)
20	Risankizumab	Skyrizi	active psoriatic arthritis
21	Roxadustat	Evrenzo	treatment of adult patients with symptomatic anaemia
22	Solriamfetol	Sunosi	wakefulness and reduce excessive daytime sleepiness
23	Somatrogon	Ngenla	growth disturbance
24	Tofacitinib	Xeljanz	active polyarticular juvenile idiopathic arthritis
25	Tralokinumab	Adtralza	moderate to severe atopic dermatitis
26	Upadacitinib	Rinvoq	moderate to severe atopic dermatitis
27	Upadacitinib	Rinvoq	active ankylosing spondylitis (AS)
28	Upadacitinib	Rinvoq	active psoriatic arthritis

Table 4: Time to availability HTA

	Number of Drugs	Timeline (in days)
Average time to availability for HTA IPHA medicines in 2022	14	825

Sr. No.	Drug Name	Brand Name	Quick indication
1	Atezolizumab	Tecentriq	Breast Cancer
2	Atezolizumab	Tecentriq	extensive-stage small cell lung cancer (ES-SCLC)
3	Avelumab	Bavencio	locally advanced or metastatic urothelial carcinoma
4	Axicabtagene Ciloleucef	Yescarta	relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL)
5	Brentuximab vedotin	Adcetris	CD30+ Hodgkin's lymphoma combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
6	Daratumumab	Darzalex	non-metastatic castration resistant prostate cancer (nmCRPC)
7	Darolutamide	Nubeqa	symptomatic chronic heart failure
8	Empagliflozin	Jardiance	Major Depressive Disorder
9	Esketamine	Spravato	moderate to severe plaque psoriasis
10	Risankizumab	Skyrizi	multiple sclerosis (SPMS)
11	Siponimod	Mayzent	wild-type or hereditary transthyretin amyloidosis
12	Tafamidis	Vyndaqel	moderate to severe plaque psoriasis
13	Tildrakizumab	Ilumetri	
	Venetoclax plus	Venclyxto plus	
14	obinutuzumab	Gazyvaro	for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.

Table 5: Time to availability Orphan medicines

	Number of Drugs	Timeline (in days)
Average time to availability for IPHA orphan medicines in 2022	9	775

Sr. No.	Drug Name	Brand Name	Quick indication
1	Axicabtagene Ciloleucel Blinatumomab	Yescarta	relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL)
2	Brentuximab	Blincyto	high-risk first-relapsed Ph- CD19+ B-precursor acute lymphoblastic leukaemia
3	vedotin Brentuximab	Adcetris	CD30+ cutaneous T-cell lymphoma (CTCL)
4	vedotin Brentuximab	Adcetris	previously untreated systemic anaplastic large cell lymphoma (sALCL)
5	vedotin	Adcetris	CD30+ Hodgkin's lymphoma
6	Daratumumab	Darzalex	combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
7	Pomalidomide	Imnovid	multiple myeloma
8	Somatrogon	Ngenla	growth disturbance
9	Tafamidis	Vyndaqel	wild-type or hereditary transthyretin amyloidosis

Table 6: Time to availability oncology medicines

	Number of Drugs	Timeline (in days)
Average time to availability for IPHA oncology medicines in 2022	17	681

Sr.No.	Drug Name	Brand Name	Quick indication
1	Atezolizumab	Tecentriq	Breast Cancer
2	Atezolizumab	Tecentriq	extensive-stage small cell lung cancer (ES-SCLC)
3	Avelumab	Bavencio	locally advanced or metastatic urothelial carcinoma
4	Axicabtagene Ciloleucef	Yescarta	relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL)
5	Blinatumomab	Blincyto	high-risk first-relapsed Ph- CD19+ B-precursor acute lymphoblastic leukaemia
6	Brentuximab vedotin	Adcetris	CD30+ cutaneous T-cell lymphoma (CTCL)
7	Brentuximab vedotin	Adcetris	previously untreated systemic anaplastic large cell lymphoma (sALCL)
8	Brentuximab vedotin	Adcetris	CD30+ Hodgkin's lymphoma combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
9	Daratumumab	Darzalex	
10	Darolutamide	Nubeqa	non-metastatic castration resistant prostate cancer (nmCRPC)
11	Entrectinib	Rozlytrek	ROS1-positive advanced non-small cell lung cancer (NSCLC)

12	Lorlatinib	Lorviqua	1L ALK positive NSCLC
	Nivolumab plus Ipilimumab plus platinum-doublet	Opdivo® plus	
13	chemotherapy	Yervoy	metastatic non-small cell lung cancer (NSCLC)
14	Pembrolizumab	Keytruda	classical Hodgkin Lymphoma
	Pertuzumab and		
15	trastuzumab	Phesgo	Early and metastatic breast cancer
16	Pomalidomide	Imnovid	multiple myeloma
		Venclyxto	
	Venetoclax plus	plus	for the treatment of adult patients with previously untreated
17	obinutuzumab	Gazyvaro	chronic lymphocytic leukaemia.